Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Free Cash Flow (2016 - 2025)

Marker Therapeutics (MRKR) has disclosed Free Cash Flow for 11 consecutive years, with -$2.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Free Cash Flow fell 328.47% to -$2.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$14.8 million, a 74.08% decrease, with the full-year FY2024 number at -$10.9 million, down 5.5% from a year prior.
  • Free Cash Flow was -$2.7 million for Q3 2025 at Marker Therapeutics, down from -$1.9 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $4.9 million in Q3 2023 to a low of -$14.6 million in Q1 2022.
  • A 5-year average of -$4.6 million and a median of -$4.5 million in 2022 define the central range for Free Cash Flow.
  • Biggest YoY gain for Free Cash Flow was 210.17% in 2023; the steepest drop was 748.81% in 2023.
  • Marker Therapeutics' Free Cash Flow stood at -$6.9 million in 2021, then crashed by 37.26% to -$9.5 million in 2022, then skyrocketed by 75.84% to -$2.3 million in 2023, then plummeted by 104.07% to -$4.7 million in 2024, then skyrocketed by 41.83% to -$2.7 million in 2025.
  • Per Business Quant, the three most recent readings for MRKR's Free Cash Flow are -$2.7 million (Q3 2025), -$1.9 million (Q2 2025), and -$5.5 million (Q1 2025).